# 10× HIGHER HIT RATES AT 3–10× LOWER COSTS: ACCELERATING LIGAND DISCOVERY WITH ML-GUIDED SYNTHESIS & SCREENING

<u>Greta Klejborowska<sup>1</sup></u>, Łukasz Szczupak<sup>1</sup>, Jan Kulczycki<sup>1</sup>, Łukasz Sztukiewicz<sup>1</sup>, Piotr Setny<sup>2</sup>, Michał Michalski<sup>2</sup>, Karolina Zakrzewska<sup>2</sup>, Jarosław Walczak<sup>2</sup>, Michał Komorowski<sup>2</sup>, Michał Mońka<sup>1</sup>, Jan Rzymkowski<sup>1</sup>, Paulina Wach<sup>1</sup>, Paweł Włodarczyk-Pruszyński<sup>1</sup>, Stanisław Jastrzębski<sup>1</sup>, Piotr Byrski<sup>1</sup>

> <sup>1</sup>Molecule.one, Warsaw, Poland, <u>q.klejborowska@molecule.one</u> <sup>2</sup>Inventro.co, Białystok, Poland

## Rapid & reliable hit generation with Direct-to-biology-SpaceM1


- Unique & highly novel molecular space of ~100M compounds and still growing
- First chemical space built using deep learning models trained on proprietary HTE lab data of over **300,000 reactions**
- Rapid turnaround (fastest subset from order to measured biological activity in 4 weeks)
- Compounds starting from <\$10</li>

In comparative virtual screening $^{\#}$  on 12 protein targets with ~395 randomly selected compounds from commercial reference space and D2B-SpaceM1; D2B-SpaceM1 showed on average higher hit rates:


<b>Target</b> (examples)	D2B-SpaceM1 docking hit rate**	C-Ref* docking hit rate**	Novel to C-Ref (Tanimoto < 0.75)	Highly novel to C-Ref (Tanimoto < 0.5 & Different Scaffold)
PRMT5	10.4%	1.0%	60.0%	10.8%
KRAS(G12C)	6.6%	0.0%	48.6%	18.9%
LRRK2	4.3%	0.3%	54.5%	21.2%
mGluR5-5M	8.1%	0.5%	43.5%	10.1%
BTK	24.3%	3.6%	46.7%	15.6%

\*Based on ligand efficiency; \*C-Ref - commercial reference, \*\*Hit rates calculated using ligand efficiency with threshold of activity was set dynamically as at max(0.4, thr\_chembl), where thr\_chembl is median ligand efficiency of top 10% most active compounds stored in Chembl. Compounds were randomly sampled from each space.

### Hit identification & confirmation from virtual screen in 5 weeks



#### Hit candidates selection based on **INVENTRO AI Predictive Models**




- Efficient exploration of 10<sup>12</sup> cmpd spaces
- On-target activity hit rate for up to 30%
- Cost (Al model & biological assay): ~\$100 per one active
- Time: hours/days
- Multiple activities

#### (§) INVENTRO

#### Direct-to-biology (D2B) plate synthesis

- D2B: parallel micro-scale synthesis in well plates followed by minimal work-up
- Molecule's one HTE lab: on average 13,000 reactions/weekly
- Synthesis success rate ~92% (84/92)
- Feasibility based on proprietary experimental data
- Cmpds delivered in 384-well plates (1–10 mM)




#### Summary:

- Largest & most novel D2B space, built on extensive HTE reaction data
- Strong (0.89 R<sup>2</sup>) correlation between D2B crude activity and purified IC<sub>50</sub> ranking
- Hit activity up to sub-nM level, hit rate 18%
- End-to-end workflow is very rapid, enabling experimental hitID and confirmation within weeks, not months
- Workflow applicable also to hit expansion and hit2lead

#### Hit resynthesis & confirmatory assay

- Fast turnaround: hits resynthesized, purified and delivered within 1 week of D2B assay results
- All purified hits confirmed active at Inventro
- Potent hits\* down to sub-nM level (IC<sub>50</sub> distribution: 2 at  $\mu$ M, 2 at sub- $\mu$ M, 2 at nM, 1 at sub-nM)



\*No prior literature reports for these structures; for O4, SciFinder similarity 85

:::: molecule.one


to the closest known



Discover Molecule.one's offer — scan here

## Rapid biological screening

- Initial 100× dilution screen in ADP-Glo → 12 compounds with CLK1 activity <10%
- 2nd run at 1,000× and 10,000× dilutions
- Outcome: 11 compounds inhibited CLK1 activity >50%; hit rate: 18% (AI-prioritized), 12% (full grid)



the absence of inhibitor, control CLK-IN-T3 at 1 µM

Scan to schedule a meeting with us!

